ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings
ADMA Biologics is experiencing challenges in the IVIG market, resulting in flat revenue for Q1 and a reduction in guidance for 2026. The company's share price has declined over 50% year-to-date. Despite these issues, ASCENIV has shown strong performance with significant revenue growth, helping to mitigate some of the losses from BIVIGAM.
- ▪ADMA Biologics reported flat Q1 revenue and cut its 2026 guidance.
- ▪The company's shares have dropped more than 50% year-to-date.
- ▪ASCENIV's revenue grew by 28% year-over-year, while BIVIGAM faced a 54% decline.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
